Back to results
US 2021/0079015 A1Published application
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
AssigneeNovartis AG
InventorsJiping FU, Mika LINDVALL, James R. MANNING, Glenn MCENROE
Life of this patent
Estimating the term…
Abstract
The invention provides compounds of Formula (I) n R3b Z W Q R3a H Y N R1 R4 R2 O (I) as described herein, along with stereoisomeric forms salts, hydrates, solvates, and salts thereof and pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.
Claims15
A compound of formula (I):
- a stereoisomer thereof or a pharmaceutically acceptable salt thereof;
- wherein:
- R1 is aryl or heteroaryl containing one or more heteroatoms each independently selected from N, O and S as a ring member, said aryl or heteroaryl being unsubstituted or substituted with one or more substituents independently selected from C1-8alkyl, C3-8-cycloalkyl, cyano, C1-8alkoxy, haloC1-8alkyl, and halogen;
- Y is CH, C— C1-8alkyl, or N;
- W is C or CH if Y is N, and W is O when Y is CI or C—C1-8alkyl;
- Q is O, N or NH;
- Z is O if Q is N or NH;
- and Z is N or NH, if Q is O;
- n indicates an integer of 1 or 2;
- each R2, R3a and R3b are independently H or C1-C8 alkyl or R3a and R3b can be taken together to form a C3-8cycloalkyl;
- R4 is a 3-9 membered saturated monocyclic, bridged, unbridged or spiro bicyclic ring that can optionally contain one or more heteroatoms each independently selected from N, O and S as a ring member, and can be unsubstituted or substituted by one or more groups independently selected from —C1-C8alkyl, hydroxyC1-C8alkyl, —NR52, —CN, —COR5, —COOR5, —CONR52, —OH, oxo, halo, —SOR5, −SO2OR5, —SO2NR52, —(C1-C8alkylene)m-R5, —(C1-C8alkylene)m-R6, —(C1-C8alkylene)m-O—R6, —(C1-C8alkylene)m-SO2—R6 and —O—(C1-C8alkylene)m-R6;
- each R5 is independently selected from C1-C8alkyl, —COC1-C8alkyl, —COR6, hydroxyC1-C8alkyl, C1-C8alkoxy, haloC1-C8alkyl, —SO2C1-C8alkyl, aryl and heteroaryl;
- each of said aryl or heteroaryl which can be unsubstituted or substituted by one or more groups independently selected from C1-C8alkyl, —OH, C1-C8alkoxy and halo;
- each R6 is independently heteroaryl or a 3-9 membered saturated monocyclic, bridged, unbridged or spiro bicyclic ring that can optionally contain one or more heteroatoms each independently selected from N, O and S as a ring member, and can be substituted by one or more groups independently selected from C1-C8alkyl, CN, —OH, C1-C8alkoxy and halo;
- m is 0 or 1;
- or R4 is phenyl, said phenyl being unsubstituted or substituted with one or more substituents independently selected from halogen, cyano, hydroxy, C1-6alkyl, C1-6alkoxy, C3-8cycloalkyl, haloC1-6alkoxy and halo C1-6alkyl;
- C3-8-cycloalkyl, −SO2OR5, and —SO2NR52;
- or R4 is heteroaryl, said heteroaryl being unsubstituted or substituted with one or more substituents independently selected from halogen, cyano, hydroxy, C1-6alkyl, C1-6alkoxy, C3-8cycloalkyl, haloC1-6alkoxy and halo C1-6alkyl;
- or C3-8-cycloalkyl;
- and
- represents a single or double bond.
18 more elements
-17. (canceled)
Dependencies are inferred from the claim text.